尿素生成增加揭示PICU中强化营养的代谢不耐受:PEPaNIC随机对照试验的二次分析
该研究为PEPaNIC-RCT二次分析,纳入1440例PICU患者(新生儿至17岁),随机分为早期PN组和晚期PN组。在665例早期PN和663例晚期PN未接受RRT的患者中,早期PN组前11天尿素浓度和尿素/肌酐比(UCR)均更高。第一周最大UCR每增加30年龄标准化单位,新发感染风险增加(OR 1.746, 95%CI 1.353-2.265),PICU存活出院可能性降低(HR 0.745, 95%CI 0.671-0.824),90天死亡率增加(OR 1.432, 95%CI 1.029-1.993),并部分解释早期PN的危害。提示尿素或UCR或可用于识别对强化营养代谢不耐受的危重患儿。
要点
- PICU患儿(新生儿至17岁)早期补充肠外营养较晚期PN在前11天尿素和UCR更高,提示氨基酸负荷下尿素生成增加。
- 第一周最大UCR每增加30年龄标准化单位,新发感染风险OR 1.746(95%CI 1.353-2.265),90天死亡率OR 1.432(95%CI 1.029-1.993)。
- 第一周最大UCR升高独立关联PICU存活出院可能性降低(HR 0.745, 95%CI 0.671-0.824)和住院存活出院可能性降低(HR 0.778, 95%CI 0.703-0.860)。
- 尿素浓度升高结果与UCR类似,早期PN的危害部分由尿素/UCR升高统计解释。
- 尿素或UCR有望纳入动态监测工具,指导危重患儿营养支持的时机和剂量,但尚需前瞻性验证。
适用人群与场景
- PEPaNIC-RCT纳入的PICU患者(新生儿至17岁),来自Leuven、Rotterdam、Edmonton三个PICU中心。
- 本二次分析仅纳入未接受肾脏替代治疗(RRT)且有UCR数据的患者:早期PN组665例,晚期PN组663例。
诊断标准与关键阈值
- 原文未提及诊断标准或启动/停止阈值;研究使用血浆/血清尿素和尿素/肌酐比(UCR)作为暴露指标,并以第一周最大值进行统计分析。
- UCR效应量以每30年龄标准化单位表示(OR/HR per 30 age-normalized units)。
处置流程与药物剂量
- 原文未提及具体营养方案剂量、给药途径、频次或目标值;仅描述随机分组为早期PN(对不足肠内营养早期补充肠外营养)与晚期PN( withholding parenteral nutrition for one week)。
红旗征与不能漏的情况
- 原文未提及需要立刻处理或不能漏诊的红旗征及对应处理。
研究设计与关键结果
- 研究类型:PEPaNIC-RCT的二次分析;样本量:1440例随机,665例早期PN和663例晚期PN非RRT患者有UCR数据;三中心PICU。
- 主要终点:新发感染和PICU依赖持续时间;第一周最大UCR每增加30年龄标准化单位,新发感染调整OR 1.746(95%CI 1.353-2.265, p<0.0001),PICU存活出院调整HR 0.745(95%CI 0.671-0.824, p<0.0001)。
- 安全终点:90天死亡率调整OR 1.432(95%CI 1.029-1.993, p=0.033);次要终点:住院存活出院调整HR 0.778(95%CI 0.703-0.860, p<0.0001)。
- 早期PN组前11天尿素浓度和UCR均高于晚期PN组;尿素浓度升高结果与UCR类似。
- 第一周最大UCR升高统计解释(部分)早期PN随机干预的任何效应。
证据类型、等级与局限
- 证据类型:RCT(PEPaNIC-RCT)的二次分析;原文未给出证据等级或推荐强度。
- 局限:二次分析、仅纳入非RRT且有UCR数据的患者(665/1440早期PN和663/1440晚期PN),尿素/UCR为观察性暴露指标,统计解释不等同于因果中介;原文未报告其他局限。
对床旁实践的改变
- 原文提示:PICU中早期补充肠外营养期间监测尿素或UCR或有助于识别对强化营养代谢不耐受的患儿,从而调整营养支持的时机和剂量;该用途尚需前瞻性验证,原文未给出具体监测频率或干预阈值。
- 适用人群为PICU中未接受RRT的危重患儿(新生儿至17岁);接受RRT者未纳入本分析。
指南或共识出处
- PEPaNIC-RCT(ClinicalTrials.gov NCT01536275, registered February 2012);本文为发表于Crit Care的二次分析,原文未提及具体指南或共识名称。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: As compared with withholding parenteral nutrition (PN) for one week (late-PN), early supplementation of insufficient enteral nutrition with PN (early-PN) increased infection risk and delayed recovery of critically ill children in the PEPaNIC-RCT, with harm attributed to higher amino acid doses. We hypothesized that this harm could be explained by increased ureagenesis, revealing metabolic intolerance to enhanced feeding.
METHODS: This is a secondary analysis of the PEPaNIC-RCT (ClinicalTrials.gov-NCT01536275), in which patients (newborn-17 years) admitted to pediatric intensive care units (PICUs, Leuven-Rotterdam-Edmonton) were randomly allocated to early-PN or late-PN. For patients not receiving renal replacement therapy (RRT), we documented plasma/serum urea and urea/creatinine ratio (UCR) profiles throughout two PICU weeks and investigated whether an increased maximum value in the randomized intervention window (first week) statistically explained harm by early-PN, via multivariable logistic regression and Cox proportional hazards analyses. We studied risk of new infections and duration of PICU dependency as primary outcomes, 90-day mortality as safety outcome, and duration of hospital dependency as secondary outcome.
RESULTS: Of 1440 PEPaNIC-patients recruited, 665 early-PN and 663 late-PN non-RRT patients had UCR data. Urea concentrations and UCRs were higher in early-PN than in late-PN patients throughout the first 11 days. Higher first week maximum UCR independently associated with (OR/HR expressed per 30 age-normalized units) an increased risk of new infection [adjusted OR (95%CI) 1.746 (1.353-2.265), p < 0.0001], lower likelihood of earlier live PICU [adjusted HR 0.745 (0.671-0.824), p < 0.0001] and hospital discharge [adjusted-HR 0.778 (0.703-0.860), p < 0.0001], and increased 90-day mortality [adjusted OR 1.432 (1.029-1.993), p = 0.033], and statistically explained (part of) any effect of the randomized intervention. Similar results were obtained for urea concentrations.
CONCLUSIONS: Increased plasma/serum urea or UCR with early-PN partially explained the harm by early-PN, suggesting these may identify critically ill children metabolically intolerant to enhanced nutrition. This opens perspectives for incorporating urea or UCR into a dynamic monitoring tool to guide the appropriate timing and dosing of nutritional support.
TRIAL REGISTRATION: ClinicalTrials.gov NCT01536275, registered February 2012.
参考来源
- Vanhorebeek I, Umman Serin N, Verbruggen SCAT, et al. Increased ureagenesis revealing metabolic intolerance to enhanced nutrition in the PICU: a secondary analysis of the PEPaNIC RCT. Crit Care. 2026. PMID: 42791581. doi:10.1186/s13054-026-06345-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。